Name (Synonyms) | Correlation |
---|
There is one clinical trial.
The aim of this study is to investigate the prevalence and possible risk factors of the occurrence of a DVT in 12 intubated and mechanically ventilated COVID-19 patients admitted to the ICU at a single time point (29/03/2020).
Description: to investigate the prevalence of a DVT in patients at the ICU.
Measure: the prevalence of a DVT in patients at the ICU. Time: 1 day at ICUDescription: evaluate pO2 and pCO2 (mmHg) in patients with and without a DVT
Measure: Oxygen partial pressure and Carbon dioxide partial pressure levels in the blood Time: 1 day at ICUDescription: evaluate Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels (mmol/l) in patients with and without a DVT
Measure: Potassium, Sodium, Calcium, Bicarbonate, Base excess, Lactate levels in the blood Time: 1 day at ICUDescription: evaluate glucose, haemoglobin, ureum, creatinine, total bilirubin levels (mg/dl) in patients with and without a DVT
Measure: glucose, haemoglobin, ureum, creatinine, total bilirubin levels in the blood Time: 1 day at ICUDescription: evaluate oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood (%) in patients with and without a DVT
Measure: oxygen saturation, basophils, eosinophils, monocytes, neutrophils, haematocrit and prothrombine levels in the blood Time: 1 day at ICUDescription: evaluate white blood cells (x 10*9/L), red blood cells (x 10*12/L) and platelets levels (x 109/L) in the blood in patients with and without a DVT
Measure: white blood cells, red blood cells and platelets in the blood Time: 1 day at ICUDescription: evaluate PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L) in the blood in patients with and without a DVT
Measure: PT (%)aPTT (sec)Fibrinogen (g/L)D-dimers (mg/L) PT (INR) (ratio) AST (U/L)ALT (U/L)Lactate dehydrogenase (U/L)Troponin T (ng/L)CRP (mg/L)Ferritin (mg/L)in the blood Time: 1 day at ICUDescription: revalence of co morbidities such as Cardiovascular disease, n (%) Hypertension, n (%) Diabetes, n (%) Respiratory disease, n (%) Malignancy, n (%) Chronic renal disease, n (%) Chronic liver disease, n (%) Chronic bowel disease, n (%) Chronic nerve disease, n (%) Cerebrovascular disease, n (%) HIV/AIDS, n (%) Haematological disease, n (%) Obesity, n (%) Rheumatological disease, n (%) Dementia, n (%) in patients with and without a DVT admitted at the ICU in 1 day
Measure: prevalence of co-morbidities Time: 1 day at ICUDescription: prevalence of vital signs such Temperature (°C) Breathing rate (#/min) Systolic blood pressure (mmHg) Mean arterial blood pressure (mmHg) Heart rate (#/min) Glasgow Coma Scale in patients with and without a DVT
Measure: prevalence of vital signs at icu admission Time: at ICU admissionDescription: prevalance of complications such as ARDS Acute kidney failure Acute heart failure Septic shock Secondary infection Seizure Stroke Hyperglaecemia Hypoglaecemia during ICU stay in patients with and without DVT
Measure: prevalence of complications during icu stay Time: from ICU admission to cross sectional moment (29/3/2020)Description: evaluation of treatment such as Antiviral treatment Antibiotic treatment Antifungal treatment Corticosteroid treatment CRRT IVIg treatment Plaquenil treatment during ICU stay in patients with and without DVT
Measure: evaluation of treatment Time: from ICU admission to cross sectional moment (29/3/2020)Description: evaluation of the oxygen therapy such as Invasive mechanical ventilation FiO2 (mmHg) PEEP Length of ventilationA ECMO Invasive mechanical ventilation + ECMO Vasopressor/inotropic support Neuromuscular blocking agents Prone ventilation in patients with and without DVT
Measure: evaluation of the oxygen therapy Time: from ICU admission to cross sectional moment (29/3/2020)